You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Primary refractory

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lymphoma, Primary Effusion Trial run by the National Cancer Institute (NCI) (Daratumumab SC)

Not yet recruiting
  • Lymphoma, Primary Effusion
  • Daratumumab SC
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jun 23, 2023

Non Hodgkin Lymphoma Trial in Cologne, Essen (CTL019)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • Cologne, Germany
  • +1 more
Mar 2, 2022

Relapsed or Refractory (R/R) Primary CNS Lymphoma Trial in Nanjing (thiotepa combined with pomalidomide)

Recruiting
  • Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
  • thiotepa combined with pomalidomide
  • Nanjing, Jiangsu, China
    Jiangsu Province People's Hospital.
Jun 27, 2023

Diffuse Large B Cell Lymphoma Trial (Polatuzumab Vedotin)

Withdrawn
  • Diffuse Large B Cell Lymphoma
  • Polatuzumab Vedotin
  • (no location specified)
May 3, 2022

Refractory CNS Lymphoma, Relapsed Primary CNS Lymphoma, Primary CNS Lymphoma Trial in Hangzhou (Nivolumab)

Active, not recruiting
  • Refractory Central Nervous System Lymphoma
  • +2 more
  • Hangzhou, Zhejiang, China
    Jianmin Zhang
Jul 3, 2022

Primary CNS Lymphoma, Secondary CNS Lymphoma, Relapsed Cancer Trial in Miami (drug, procedure, radiation)

Not yet recruiting
  • Primary Central Nervous System Lymphoma
  • +3 more
  • Miami, Florida
    Miami Cancer Institute at Baptist Health, Inc.
Dec 23, 2022

Neuroblastoma Trial in United States (TPI 287, Temozolomide, Irinotecan)

Terminated
Has Results
  • Neuroblastoma
  • TPI 287
  • +2 more
  • Phoenix, Arizona
  • +7 more
Apr 20, 2022

Malignant Melanoma Trial in Germany, Italy (4SC-202 in combination with Pembrolizumab)

Completed
  • Malignant Melanoma
  • 4SC-202 in combination with Pembrolizumab
  • Essen, Germany
  • +6 more
Feb 3, 2022

Neuroblastoma Trial in Wien, Greifswald (dinutuximab beta)

Active, not recruiting
  • Neuroblastoma
  • dinutuximab beta
  • Wien, Austria
  • +1 more
Oct 1, 2021

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma Trial

Active, not recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Jacksonville, Florida
  • +11 more
Jan 12, 2023

Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia Trial in United States

Recruiting
  • Relapsed Adult AML
  • +2 more
  • Specialty Palliative Care
  • Primary Palliative Care
  • Boston, Massachusetts
  • +3 more
Aug 12, 2022

Recurrent Adult Hodgkin Lymphoma Trial in Duarte (biological, drug, other, procedure)

Active, not recruiting
  • Recurrent Adult Hodgkin Lymphoma
  • basiliximab
  • +8 more
  • Duarte, California
    City of Hope Medical Center
Mar 17, 2022

Multiple Myeloma, Primary Plasma Cell Leukemia Trial in Shanghai (Experimental: CAR-T cells Infusion)

Not yet recruiting
  • Multiple Myeloma
  • Primary Plasma Cell Leukemia
  • Experimental: CAR-T cells Infusion
  • Shanghai, China
    Shanghai Changzheng Hospital
Apr 20, 2023

Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell

Not yet recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • +5 more
  • Boston, Massachusetts
  • +1 more
Jun 28, 2023

Primary CNS Lymphoma Trial in London (CD19CAR T-cells)

Recruiting
  • Primary CNS Lymphoma
  • CD19CAR T-cells
  • London, United Kingdom
    University College London Hospital
Jun 13, 2022

Osteosarcoma, Ewing Sarcoma of Bone Trial in Warsaw (Regorafenib)

Recruiting
  • Osteosarcoma
  • Ewing Sarcoma of Bone
  • Warsaw, Mazovian, Poland
    Mother and Child Institute
Sep 7, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Completed
Has Results
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
Dec 21, 2022

Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma Trial in

Recruiting
  • Malignant Ovarian Epithelial Tumor
  • +9 more
  • Akt/ERK Inhibitor ONC201
  • +2 more
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
May 10, 2022

Cardiovascular Events Among Adults Relapsed or Refractory

Recruiting
  • Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
  • +9 more
  • Electronic Health Record Review
  • Houston, Texas
    M D Anderson Cancer Center
Dec 5, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Durvalumab
  • Tremelimumab
  • Houston, Texas
    M D Anderson Cancer Center
Jul 19, 2022

Brain Tumor, Primary Trial in Jinan (HLX208)

Recruiting
  • Brain Tumor, Primary
  • Jinan, Shandong, China
    Cancer Hospital Affiliated to Shandong first medical University
May 1, 2022

Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in Beijing (GNC-038)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Beijing, Beijing, China
    Beijing Tiantan Hospital, Capital Medical University
Jul 31, 2022

Hepatocellular Carcinoma, Hepatocellular Cancer, Metastatic Pancreatic Cancer Trial run by the NCI (nivolumab, tadalafil, oral

Completed
  • Hepatocellular Carcinoma
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell

Active, not recruiting
  • Recurrent Anaplastic Large Cell Lymphoma
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 30, 2023

Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

Not yet recruiting
  • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • +21 more
  • Biopsy
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 7, 2023